Total Payments
$2,356
2023 Payments
$68.27
Companies
16
Transactions
90
Medicare Patients
2,475
Medicare Billing
$367,878
Payment Breakdown by Category
Food & Beverage$2,355 (100.0%)
Education$1.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,355 | 89 | 100.0% |
| Education | $1.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $760.67 | 36 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $426.15 | 9 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $204.55 | 5 | $0 (2023) |
| Lilly USA, LLC | $176.47 | 10 | $0 (2021) |
| Neurelis, Inc. | $149.58 | 2 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $140.26 | 9 | $0 (2021) |
| OptiNose US, Inc. | $138.58 | 2 | $0 (2022) |
| UROVANT SCIENCES INC | $98.38 | 4 | $0 (2022) |
| GlaxoSmithKline, LLC. | $48.96 | 2 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $47.35 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $68.27 | 3 | Otsuka America Pharmaceutical, Inc. ($47.35) |
| 2022 | $1,057 | 23 | Neurocrine Biosciences, Inc. ($426.15) |
| 2021 | $1,231 | 64 | AbbVie Inc. ($760.67) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: NEUROLOGY | ||||||
| 01/20/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/09/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: NEUROLOGY | ||||||
| 12/14/2022 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $134.84 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/14/2022 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/06/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $29.42 | General |
| Category: Urology | ||||||
| 12/01/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/10/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: RESPIRATORY | ||||||
| 10/25/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug), Ongentys | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Neuropsychiatry | ||||||
| 10/11/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | Cash or cash equivalent | $124.80 | General |
| Category: Neuropsychiatry | ||||||
| 09/16/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $10.88 | General |
| Category: Neuropsychiatry | ||||||
| 09/16/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $4.41 | General |
| Category: Neuropsychiatry | ||||||
| 08/09/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $17.22 | General |
| Category: Urology | ||||||
| 07/19/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $27.07 | General |
| Category: Neuroscience | ||||||
| 07/19/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Neuropsychiatry | ||||||
| 07/01/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/22/2022 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $107.04 | General |
| Category: EPILEPSY | ||||||
| 06/15/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $113.96 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/24/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | Cash or cash equivalent | $112.62 | General |
| Category: Neuropsychiatry | ||||||
| 05/13/2022 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $42.54 | General |
| Category: EPILEPSY | ||||||
| 05/11/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Neuropsychiatry | ||||||
| 04/29/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/14/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.76 | General |
| Category: Neuropsychiatry | ||||||
| 03/30/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | Cash or cash equivalent | $112.82 | General |
| Category: Neuropsychiatry | ||||||
| 03/22/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $33.81 | General |
| Category: Urology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 801 | 1,026 | $258,008 | $65,362 |
| 2022 | 19 | 1,306 | 4,288 | $1.7M | $268,424 |
| 2021 | 7 | 184 | 281 | $55,743 | $19,811 |
| 2020 | 6 | 184 | 250 | $49,905 | $14,281 |
Total Patients
2,475
Total Services
5,845
Medicare Billing
$367,878
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 147 | $30,870 | $12,932 | 41.9% |
| 99493 | Follow-up psychiatric collaborative care management, subsequent calendar month, first 60 minutes | Office | 2023 | 66 | 118 | $43,070 | $11,959 | 27.8% |
| 99492 | Initial psychiatric collaborative care management, first calendar month, first 70 minutes | Office | 2023 | 65 | 66 | $24,750 | $7,101 | 28.7% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 48 | 84 | $44,081 | $6,241 | 14.2% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 29 | 48 | $37,573 | $5,186 | 13.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 60 | $8,580 | $3,789 | 44.2% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2023 | 64 | 116 | $13,300 | $3,548 | 26.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 29 | 29 | $7,337 | $3,348 | 45.6% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 16 | 16 | $10,268 | $3,168 | 30.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 45 | 57 | $22,502 | $2,970 | 13.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 22 | 24 | $3,600 | $1,403 | 39.0% |
| 99494 | Psychiatric collaborative care management per calendar month, each additional 30 minutes | Office | 2023 | 15 | 15 | $3,000 | $617.70 | 20.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 12 | 12 | $780.00 | $603.36 | 77.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $624.00 | $390.00 | 62.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 48 | 49 | $1,323 | $372.89 | 28.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 33 | 34 | $1,190 | $351.90 | 29.6% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 19 | 19 | $1,045 | $312.74 | 29.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 32 | 34 | $612.00 | $285.60 | 46.7% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 20 | 21 | $1,386 | $275.52 | 19.9% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 19 | 23 | $667.00 | $190.67 | 28.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 14 | 14 | $830.00 | $145.74 | 17.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 13 | 13 | $455.00 | $123.76 | 27.2% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 12 | 15 | $165.00 | $46.65 | 28.3% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Office | 2022 | 152 | 1,018 | $534,216 | $65,705 | 12.3% |
| 99310 | Follow-up nursing facility visit per day, typically 35 minutes | Office | 2022 | 128 | 563 | $440,700 | $53,448 | 12.1% |
About Lina Garcia, AGPCNP-C
Lina Garcia, AGPCNP-C is a Gerontology healthcare provider based in Glastonbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2018. The National Provider Identifier (NPI) number assigned to this provider is 1235606443.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lina Garcia, AGPCNP-C has received a total of $2,356 in payments from pharmaceutical and medical device companies, with $68.27 received in 2023. These payments were reported across 90 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,355).
As a Medicare-enrolled provider, Garcia has provided services to 2,475 Medicare beneficiaries, totaling 5,845 services with total Medicare billing of $367,878. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Gerontology
- Other Specialties Adult Health
- Location Glastonbury, CT
- Active Since 10/25/2018
- Last Updated 02/08/2023
- Taxonomy Code 363LG0600X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235606443
Products in Payments
- UBRELVY (Drug) $428.44
- INGREZZA (Drug) $426.15
- VRAYLAR (Drug) $239.45
- NUPLAZID (Drug) $204.55
- VALTOCO (Drug) $149.58
- NURTEC ODT (Drug) $140.26
- Xhance (Drug) $138.58
- EMGALITY (Drug) $105.06
- GEMTESA (Drug) $98.38
- TRULICITY (Drug) $70.41
- QULIPTA (Drug) $55.78
- TRELEGY ELLIPTA (Drug) $48.96
- NUEDEXTA (Drug) $47.35
- XIFAXAN (Drug) $35.63
- ZEPOSIA (Drug) $27.07
- Ozempic (Drug) $25.00
- LINZESS (Drug) $21.91
- Dayvigo (Drug) $18.65
- RYBELSUS (Drug) $17.08
- NASCOBAL (Drug) $12.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.